RECURSION PHARMACEUTICALS, INC. Financial comparisons Recursion Pharmaceuticals, Inc.
Equities
RXRX
US75629V1044
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.570 USD | +1.08% |
|
+10.98% | -33.37% |
| 09-03 | Jefferies Cuts Price Target on Recursion Pharmaceuticals to $6 From $8, Maintains Hold Rating | MT |
| 09-03 | Recursion Pharmaceuticals Says REC-994 Phase 2 Trial Shows Safety and Efficacy Trends | MT |
Main competitors
| Revenues ($) (Y-1) | Net margin (Y-1) | Operating Margin (Y-1) | ROE (Y-1) | ROA (Y-1) | Leverage (Debt/EBITDA) (Y-1) | ||
|---|---|---|---|---|---|---|---|
| 44.58M | -735.99% | -785.33% | -69.12% | -48.42% | 1.2x | ||
| 13.12B | +30.14% | +39.08% | +20.74% | +16.20% | -1.6x | ||
| 9.87B | +36.68% | +44.33% | +22.99% | +17.71% | -2.46x | ||
| 1.3B | -23.26% | -33.51% | -8.54% | -7.69% | 10.14x | ||
| 4.23B | +24.36% | +18.08% | +4.62% | +4.02% | -13.1x | ||
| 2.46B | -35.86% | -49.12% | -22.26% | -14.47% | 2.05x | ||
| 2.45B | +26.42% | +32.30% | +14.78% | +13.31% | -5.01x | ||
| 5.69B | +26.50% | +29.43% | +18.99% | +15.45% | -0.64x | ||
| 305M | -245.59% | -232.51% | - | -50.20% | -0.8x | ||
| 1.89B | +13.23% | +13.30% | +12.68% | +8.89% | -5.76x | ||
| 1.24B | -43.11% | -21.54% | -86.15% | -1.86% | 1.96x | ||
| 50.93M | -205.30% | -166.94% | -58.43% | - | 2.98x | ||
| 285M | -181.75% | -144.69% | -51.94% | -32.60% | 2.5x | ||
| 829M | +33.96% | +40.71% | +293.15% | +20.80% | 2.73x | ||
| 1.83B | +11.35% | +9.34% | +8.74% | +6.91% | -5.06x | ||
| 160M | -12.22% | -37.48% | -3.46% | -2.93% | 11.91x | ||
| Average | 2.86B | -80.03% | -77.78% | +6.45% | -3.66% | 0.06x | |
| Weighted average by Cap. | 7.37B | +0.40% | +5.62% | +13.22% | +8.07% | -1.24x |
- Stock Market
- Equities
- RXRX Stock
- Sector Recursion Pharmaceuticals, Inc.
- Financial comparisons
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition